Related Experiment Video
Updated: Aug 18, 2026
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Sarcomeric genotyping in hypertrophic cardiomyopathy
Sara L Van Driest1, Steve R Ommen, A Jamil Tajik
1Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA.
Insights
Genetic variations in hypertrophic cardiomyopathy (HCM) do not clearly predict patient phenotypes. Further research is needed to understand how genetic and environmental factors influence HCM presentation.
Area of Science:
- Cardiovascular Genetics
- Molecular Cardiology
Background:
- Hypertrophic cardiomyopathy (HCM) is a genetic heart muscle disease.
- Understanding genotype-phenotype correlations is crucial for patient management.
Purpose of the Study:
- To investigate phenotypic differences among hypertrophic cardiomyopathy (HCM) genotypes by pooling international study data.
- To identify potential genotype-specific clinical presentations in HCM patients.
Main Methods:
- A meta-analysis of published genotyping studies from November 1998 to November 2004.
- Comparison of mutation frequencies, age at diagnosis, and left ventricular wall thickness across different study populations and genotypes.
- Statistical analysis to pool and compare data.
Main Results:
- The myosin binding protein C (MYBPC3) gene was the most frequent cause of HCM across all populations.
- Mutation frequency varied by geographic origin, with the French population showing the highest rate (61%).
- No significant differences in left ventricular wall thickness or age at diagnosis were observed across genotypes.
Conclusions:
- Current phenotypic data are insufficient to differentiate between sarcomeric genotypes in HCM.
- Genetic and environmental modifiers likely play a significant role in determining individual HCM phenotypes.
- Further investigation into these modifiers is warranted.
Objective:
To pool results from studies of patients with hypertrophic cardiomyopathy (HCM) to elucidate important phenotypic differences among genotypes.
Material And Methods:
Data published from November 1998 through November 2004 were gathered and compared from unrelated study population genotyping studies from the Mayo Clinic (Rochester, Minn), Harvard Medical School (Boston, Mass), France, Germany, Sweden, Finland, and Spain. Standard statistical analysis techniques were used to pool and compare data across genotypes with respect to frequency of mutations, age at diagnosis, and degree of hypertrophy (left ventricular wall thickness).
Results:
The French study population harbored the highest frequency of mutations (61%), followed by the Mayo Clinic (38%), Harvard Medical School (36%), and Swedish (30%) study populations. For every study population, mutations in myosin binding protein C (MYBPC3) were the most common cause of HCM. Patients with a family history of HCM had mutations more frequently than those without. This pooled analysis revealed no statistically significant differences in left ventricular wall thickness or in mean age at diagnosis across all genotypes.
Conclusions:
Differentiation of sarcomeric genotypes, such as MYBPC3-HCM and MYH7-HCM, is not possible on the basis of currently reported phenotypic data. A myriad of genetic and/or environmental modifiers in addition to the primary disease-causing genetic substrate must play an important role in determining a patient's particular phenotype.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:30Cardiomyopathy II: Dilated Cardiomyopathy